Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC-CTL in Solid Tumors
NCT06524024Not yet recruiting
- Sponsor
- Zhengzhou Revo-Gene Technology
- Start
- Oct 2026
- Primary completion
- Apr 2027
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
01
Overview
Open-label, single-arm trial in solid tumor, sponsored by Zhengzhou Revo-Gene Technology. Primary endpoint: Progression-Free Survival up to 2 years. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06524024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06524024.